Figure 1a. Improved overall survival rate in CLL patients after non-myeloablative allogeneic transplantation with bendamustine, fludarabine, and rituximab conditioning (upper curve) vs. findings with fludarabine, cyclophosphamide, and rituximab conditioning (lower curve).
Figure 1b. Overall survival rate in patients with CLL associated with 17p deletion after non-myeloablative allogeneic transplantation with bendamustine, fludarabine, and rituximab conditioning (upper curve) vs. findings with fludarabine, cyclophosphamide, and rituximab conditioning (lower curve).
Figure 1c. Overall survival rate in patients with CLL after non-myeloablative allogeneic transplantation according to the use of ATG.